Jones is credited with improving diversity at the organization.
The Healthcare Businesswomen’s Association (HBA) promoted Nikki M. Jones to the position of Chief People and Diversity, Equity, and Inclusion (DE&I) Officer. Jones, who first started working with the HBA in 2009, started working with the organization to improve its DE&I two years ago and during that time, she has been credited with improving the organization’s diversity and inclusion.
In 2018, the HBA’s staff only had 16% representation for diverse workers. Since then, through the efforts of Jones, that number has risen to 36%. She also worked to improve diversity among the global volunteer membership network, increasing the number of diverse members to 34% from less than 10% several years prior. The honorees at the HBA’s annual Rising Stars and Luminaries award have also become more diverse, with about 40% of them representing diversity.
Jone also launched the HBA’s first Women of Color Wellness Summit and the Honoring Partnerships and Equity program.
Before working with HBA, Jones built up 25 years of experience working in finance and operations. She now leads a 27 person staff and provides guidance for the organization’s 12,000 members.
“Nikki’s passion for the integration of equitable and inclusive practices pushed the association to an official, more committed, and concentrated effort to support and serve women of color and underestimated populations,” said Amy Crolius, Chief Operating Officer, HBA.
Read more about Nikki M. Jones' new position here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.